Literature DB >> 24486403

NF-κB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A(2A) receptors.

Laurie Bruzzese1, Julien Fromonot1, Youlet By1, Josée-Martine Durand-Gorde1, Jocelyne Condo1, Nathalie Kipson1, Régis Guieu1, Emmanuel Fenouillet2, Jean Ruf3.   

Abstract

Hypoxia affects inflammation by modulating T-cell activation via the adenosinergic system. We supposed that, in turn, inflammation influences cell hypoxic behavior and that stimulation of T-cells in inflammatory conditions involves the concerted action of the nuclear factor κB (NF-κB) and the related hypoxia-inducible factor 1α (HIF-1α) on the adenosinergic system. We addressed this hypothesis by monitoring both transcription factors and four adenosinergic signaling parameters - namely adenosine, adenosine deaminase (ADA), adenosine A2A receptor (A2AR) and cAMP - in T-cells stimulated using phorbol myristate acetate and phytohemagglutinin and submitted to hypoxic conditions which were mimicked using CoCl2 treatment. We found that cell viability was more altered in stimulated than in resting cells under hypoxia. Detailed analysis showed that: i) NF-κB activation remained at basal level in resting hypoxic cells but greatly increased following stimulation, stimulated hypoxic cells exhibiting the higher level; ii) HIF-1α production induced by hypoxia was boosted via NF-κB activation in stimulated cells whereas hypoxia increased HIF-1α production in resting cells without further activating NF-κB; iii) A2AR expression and cAMP production increased in stimulated hypoxic cells whereas adenosine level remained unchanged due to ADA regulation; and iv) the presence of H2S, an endogenous signaling molecule in inflammation, reversed the effect of stimulation on cell viability by down-regulating the activity of transcription factors and adenosinergic immunosuppression. We also found that: i) the specific A2AR agonist CGS-21680 increased the suppressive effect of hypoxia on stimulated T-cells, the antagonist ZM-241385 exhibiting the opposite effect; and ii) Rolipram, a selective inhibitor of cAMP-specific phosphodiesterase 4, and 8-Br-cAMP, a cAMP analog which preferentially activates cAMP-dependent protein kinase A (PKA), increased T-cell immunosuppression whereas H-89, a potent and selective inhibitor of cAMP-dependent PKA, restored cell viability. Together, these data indicate that inflammation enhances T-cell sensitivity to hypoxia via NF-κB activation. This process upregulates A2AR expression and enhances cAMP production and PKA activation, resulting in adenosinergic T-cell immunosuppression that can be modulated via H2S.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenosine; Adenosine A(2A) receptor; Cell viability; Chemical hypoxia; Hydrogen sulfide

Mesh:

Substances:

Year:  2014        PMID: 24486403     DOI: 10.1016/j.cellsig.2014.01.024

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  18 in total

1.  CD47-dependent regulation of H₂S biosynthesis and signaling in T cells.

Authors:  Sukhbir Kaur; Anthony L Schwartz; Thomas W Miller; David D Roberts
Journal:  Methods Enzymol       Date:  2015-01-08       Impact factor: 1.600

2.  The plant hormone zeatin riboside inhibits T lymphocyte activity via adenosine A2A receptor activation.

Authors:  Courtney M Lappas
Journal:  Cell Mol Immunol       Date:  2014-05-12       Impact factor: 11.530

3.  Adaptative mechanism of the equilibrative nucleoside transporter 1 (ENT-1) and blood adenosine levels in elite freedivers.

Authors:  M Marlinge; D Vairo; R Guieu; F Joulia; A Bertaud; C Vernet; M Chefrour; L Bruzzese; M C Chaptal; G Mottola; A Boussuges; J J Risso; M Blot-Chabaud; M Coulange
Journal:  Eur J Appl Physiol       Date:  2020-10-14       Impact factor: 3.078

4.  Induction of antiinflammatory purinergic signaling in activated human iNKT cells.

Authors:  Jennifer C Yu; Gene Lin; Joshua J Field; Joel Linden
Journal:  JCI Insight       Date:  2018-09-06

5.  Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.

Authors:  Danielle M Lussier; Eric C Woolf; John L Johnson; Kenneth S Brooks; Joseph N Blattman; Adrienne C Scheck
Journal:  BMC Cancer       Date:  2016-05-13       Impact factor: 4.430

Review 6.  NF-κB and HIF crosstalk in immune responses.

Authors:  Laura D'Ignazio; Daniel Bandarra; Sonia Rocha
Journal:  FEBS J       Date:  2015-11-24       Impact factor: 5.542

7.  Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions.

Authors:  María de Lourdes Mora-García; Rosario García-Rocha; Omar Morales-Ramírez; Juan José Montesinos; Benny Weiss-Steider; Jorge Hernández-Montes; Luis Roberto Ávila-Ibarra; Christian Azucena Don-López; Marco Antonio Velasco-Velázquez; Vianey Gutiérrez-Serrano; Alberto Monroy-García
Journal:  J Transl Med       Date:  2016-10-26       Impact factor: 5.531

8.  Leishmania infantum Parasites Subvert the Host Inflammatory Response through the Adenosine A2A Receptor to Promote the Establishment of Infection.

Authors:  Mikhael H F Lima; Lais A Sacramento; Gustavo F S Quirino; Marcela D Ferreira; Luciana Benevides; Alynne K M Santana; Fernando Q Cunha; Roque P Almeida; João S Silva; Vanessa Carregaro
Journal:  Front Immunol       Date:  2017-07-20       Impact factor: 7.561

9.  Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors.

Authors:  Sonja Hinz; Gemma Navarro; Dasiel Borroto-Escuela; Benjamin F Seibt; York-Christoph Ammon; Elisabetta de Filippo; Azeem Danish; Svenja K Lacher; Barbora Červinková; Muhammad Rafehi; Kjell Fuxe; Anke C Schiedel; Rafael Franco; Christa E Müller
Journal:  Oncotarget       Date:  2018-02-06

10.  High homocysteine levels prevent via H2 S the CoCl2 -induced alteration of lymphocyte viability.

Authors:  Laurie Bruzzese; Emmanuel Fenouillet; Julien Fromonot; Josée-Martine Durand-Gorde; Jocelyne Condo; Nathalie Kipson; Giovanna Mottola; Pierre Deharo; Régis Guieu; Jean Ruf
Journal:  J Cell Mol Med       Date:  2016-04-08       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.